Literature DB >> 25129986

Carboplatin dosing for adult Japanese patients.

Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, Yoshinori Hasegawa.   

Abstract

Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer. Because the clearance of carboplatin strongly correlates with the glomerular filtration rate (GFR), its dosage is calculated with the Calvert formula on the basis of the patient's GFR to achieve the target area under the plasma drug concentration-time curve (AUC) for each patient. However, many lines of evidence from previous clinical studies should be interpreted with caution because different methods were used to estimate drug clearance and derive the dosage of carboplatin. There is a particularly high risk of carboplatin overdosing when the dosage is determined on the basis of standardized serum creatinine values. When deciding the dose of carboplatin for adult Japanese patients, preferred methods to assess renal function instead of directly measuring GFR include (1) 24-h urinary collection-based creatinine clearance adjusted by adding 0.2 mg/dl to the serum creatinine concentration measured by standardized methods, and (2) equation-based GFR (eGFR) with a back calculation to units of ml/min per subject. Given the limitations of serum creatinine-based GFR estimations, the GFR or creatinine clearance should be directly measured in each patient whenever possible. To ensure patient safety and facilitate a medical-team approach, the single most appropriate method available at each institute or medical team should be consistently used to calculate the dose of carboplatin with the Calvert formula.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25129986      PMCID: PMC4345715     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  18 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

Authors:  M A Bookman; W P McGuire; D Kilpatrick; E Keenan; W M Hogan; S W Johnson; P O'Dwyer; E Rowinsky; H H Gallion; R F Ozols
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

3.  Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.

Authors:  H Minami; Y Ando; H Saka; K Shimokata
Journal:  J Natl Cancer Inst       Date:  1997-07-02       Impact factor: 13.506

4.  Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.

Authors:  M Ando; H Minami; Y Ando; H Saka; S Sakai; M Yamamoto; Y Sasaki; K Shimokata; Y Hasegawa
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

5.  Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Gary R Matzke; George R Aronoff; Arthur J Atkinson; William M Bennett; Brian S Decker; Kai-Uwe Eckardt; Thomas Golper; Darren W Grabe; Bertram Kasiske; Frieder Keller; Jan T Kielstein; Ravindra Mehta; Bruce A Mueller; Deborah A Pasko; Franz Schaefer; Domenic A Sica; Lesley A Inker; Jason G Umans; Patrick Murray
Journal:  Kidney Int       Date:  2011-09-14       Impact factor: 10.612

6.  Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

Authors:  E Chatelut; P Canal; V Brunner; C Chevreau; A Pujol; A Boneu; H Roché; G Houin; R Bugat
Journal:  J Natl Cancer Inst       Date:  1995-04-19       Impact factor: 13.506

7.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

Authors:  D I Jodrell; M J Egorin; R M Canetta; P Langenberg; E P Goldbloom; J N Burroughs; J L Goodlow; S Tan; E Wiltshaw
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

8.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

9.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Authors:  A H Calvert; D R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

10.  Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule.

Authors:  Y Ando; H Minami; H Saka; M Ando; S Sugiura; S Sakai; K Shimokata
Journal:  Jpn J Cancer Res       Date:  1997-05
View more
  4 in total

1.  Hematological toxicity of carboplatin for gynecological cancer according to body mass index.

Authors:  Fernando Gutierrez; Guillermo Antonio Gonzalez-de-la-Fuente; Gloria Julia Nazco; Juana Oramas; Norberto Batista
Journal:  Eur J Clin Pharmacol       Date:  2016-06-10       Impact factor: 2.953

2.  Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma.

Authors:  Ayana Tomono; Kaori Ito; Takahiro Hayashi; Maiko Ando; Yosuke Ando; Masahiro Tsuge; Akinao Okamoto; Yoko Inaguma; Masataka Okamoto; Nobuhiko Emi; Shigeki Yamada
Journal:  Cancer Chemother Pharmacol       Date:  2016-06-20       Impact factor: 3.333

3.  <Editors' Choice> Clinical impact of standardized creatinine on dose adjustment of capecitabine.

Authors:  Ayaka Ito; Kazuya Ichikawa; Masayuki Miyazaki; Atsunobu Sagara; Toshiki Motegi; Yuichi Ando; Koji Senzaki; Taku Nagai; Kiyofumi Yamada
Journal:  Nagoya J Med Sci       Date:  2022-08       Impact factor: 0.794

4.  Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma.

Authors:  Yixiang Zhu; Puyuan Xing; Shouzheng Wang; Di Ma; Yuxin Mu; Xue Li; Ziyi Xu; Junling Li
Journal:  Thorac Cancer       Date:  2018-01-29       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.